Chinese Science Bulletin

, Volume 58, Issue 15, pp 1760–1766 | Cite as

Polymerase mutations rtN238R, rtT240Y and rtN248H of hepatitis B virus decrease susceptibility to adefovir

  • Bo Qin
  • RongJuan Pei
  • TingTing He
  • ZhaoHui Huang
  • GuoShao Pan
  • ChunYu Tu
  • MengJi Lu
  • XinWen Chen
Open Access
Article Virology


Long term antiviral therapy with nucleos(t)ide analogs (NAs) may lead to the emergence of drug-resistance viral mutants in chronic hepatitis B virus (HBV) patient. The purpose of this study was to identify adefovir dipivoxil (ADV) resistance mutations of HBV polymerase and determine effective drugs to replace ADV. The reverse transcriptase (RT) coding region was PCR-amplified using HBV DNA extracted from patient blood samples and sequenced. Nineteen substitution mutations were detected. Among them, rtN238R, rtT240Y and rtN248H were often observed in patients receiving ADV administration. These three potential drug resistant sites were introduced into HBV replication-competent plasmids. The in vitro susceptibility of both wild-type (WT) and mutant-type (MT) HBV to NAs was analyzed by Southern blotting and quantitative real-time PCR. The rtN238R, rtT240Y and rtN248H substitutions had no obvious effect on HBV DNA replication or gene expression. The in vitro susceptibility analysis showed that rtN238R, rtT240Y and rtN248H substitutions were responsible for the reduced susceptibility to ADV, and demonstrated a 5.42-, 2.89- and 5.72-fold increase in resistance towards ADV, respectively. However, HBV harbored these mutations retained normal susceptibility to LMV, LdT, ETV and TDF.


hepatitis B virus resistance mutation adefovir dipivoxil (ADV) 


  1. 1.
    Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol, 2007, 13: 48–64Google Scholar
  2. 2.
    Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: Removal of genome-linked protein. J Virol, 2007, 81: 6164–6174CrossRefGoogle Scholar
  3. 3.
    Mizokami M, Orito E, Ohba K, et al. Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol, 1997, 44(Suppl 1): S83–90CrossRefGoogle Scholar
  4. 4.
    Lee W M. Hepatitis B virus infection. N Engl J Med, 1997, 337: 1733–1745CrossRefGoogle Scholar
  5. 5.
    Behal R, Jain R, Behal K K, et al. Seroprevalence and risk factors for hepatitis B virus infection among general population in northern India. Arq Gastroenterol, 2008, 45: 137–140CrossRefGoogle Scholar
  6. 6.
    Mahoney F J. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev, 1999, 12: 351–366Google Scholar
  7. 7.
    Schildgen V, Ziegler S, Tillmann R L, et al. Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance-A scholarly case. Virol J, 2010, 7: 167CrossRefGoogle Scholar
  8. 8.
    Summers J, Mason W S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell, 1982, 29: 403–415CrossRefGoogle Scholar
  9. 9.
    Gunther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus. Adv Virus Res, 1999, 52: 25–137CrossRefGoogle Scholar
  10. 10.
    Yuen M F, Lai C L. Treatment of chronic hepatitis B. Lancet Infect Dis, 2001, 1: 232–241CrossRefGoogle Scholar
  11. 11.
    Fung J, Lai C L, Seto W K, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother, 2011, 66: 2715–2725CrossRefGoogle Scholar
  12. 12.
    Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 2009, 137: 1593–1608CrossRefGoogle Scholar
  13. 13.
    Zoulim F. Antiviral therapy of chronic hepatitis B. Antiviral Res, 2006, 71: 206–215CrossRefGoogle Scholar
  14. 14.
    Kwon H, Lok A S. Hepatitis B therapy. Nat Rev, 2011, 8: 275–284Google Scholar
  15. 15.
    Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “Fingers” Subdomain of the viral polymerase selected as a consequence of mutations in the overlappings gene. Virology, 2002, 299: 88–99CrossRefGoogle Scholar
  16. 16.
    Brunelle M N, Jacquard A C, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 2005, 41: 1391–1398CrossRefGoogle Scholar
  17. 17.
    Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol, 2006, 80: 643–653CrossRefGoogle Scholar
  18. 18.
    Osiowy C, Villeneuve J P, Heathcote E J, et al. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol, 2006, 44: 1994–1997CrossRefGoogle Scholar
  19. 19.
    Leung N. Viral resistance in HBV infection: Diagnosis, implications and management. Trop Gastroenterol, 2008, 29: 123–128Google Scholar
  20. 20.
    Amini Bavil Olyaee S, Herbers U, Sheldon J, et al. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology, 2009, 49: 1158–1165CrossRefGoogle Scholar
  21. 21.
    Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther, 2005, 10: 727–734Google Scholar
  22. 22.
    Delaney W E, Ray A S, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother, 2006, 50: 2471–2477CrossRefGoogle Scholar
  23. 23.
    Wu C, Deng W, Deng L, et al. Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol, 2012, 86: 4658–4669CrossRefGoogle Scholar
  24. 24.
    Lei Y C, Hao Y H, Zhang Z M, et al. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol, 2006, 12: 4492–4497Google Scholar
  25. 25.
    Qiu J, Qin B, Rayner S, et al. Novel evidence suggests hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol Sin, 2011, 26: 131–138CrossRefGoogle Scholar
  26. 26.
    Kain S R. Use of secreted alkaline phosphatase as a reporter of gene expression in mammalian cells. Methods Mol Biol, 1997, 63: 49–60Google Scholar
  27. 27.
    Pan X B, Wei L, Han J C, et al. Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production. Antiviral Res, 2011, 89: 109–114CrossRefGoogle Scholar
  28. 28.
    Guarnieri M, Kim K H, Bang G, et al. Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol, 2006, 80: 587–595CrossRefGoogle Scholar
  29. 29.
    Meng Z, Xu Y, Wu J, et al. Inhibition of hepatitis B virus gene expression and replication by endoribonuclease-prepared siRNA. J Virol Methods, 2008, 150: 27–33CrossRefGoogle Scholar
  30. 30.
    Untergasser A, Zedler U, Langenkamp A, et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology, 2006, 43: 539–547CrossRefGoogle Scholar
  31. 31.
    Santantonio T, Fasano M, Durantel S, et al. Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B. Antivir Ther, 2009, 14: 557–565Google Scholar
  32. 32.
    Margeridon Thermet S, Shulman N S, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis, 2009, 199: 1275–1285CrossRefGoogle Scholar
  33. 33.
    Milazzo L, Corbellino M, Foschi A, et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: Successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis, 2012, 14: 95–98CrossRefGoogle Scholar
  34. 34.
    Wu C, Zhang X, Tian Y, et al. Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication. J Gen Virol, 2010, 91: 483–492CrossRefGoogle Scholar
  35. 35.
    Lok A S. Hepatitis B infection: Pathogenesis and management. J Hepatol, 2000, 32: 89–97CrossRefGoogle Scholar
  36. 36.
    Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs, 1999, 58: 101–141CrossRefGoogle Scholar
  37. 37.
    Liu B M, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive chinese patients. Antiviral Res, 2010, 85: 512–519CrossRefGoogle Scholar
  38. 38.
    Tan J, Degertekin B, Wong S N, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol, 2008, 48: 391–398CrossRefGoogle Scholar
  39. 39.
    Galmarini C M, Mackey J R, Dumontet C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Leukemia, 2001, 15: 875–890CrossRefGoogle Scholar
  40. 40.
    Cha C K, Kwon H C, Cheong J Y, et al. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol, 2009, 81: 417–424CrossRefGoogle Scholar
  41. 41.
    Lee Y S, Suh D J, Lim Y S, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 2006, 43: 1385–1391CrossRefGoogle Scholar

Copyright information

© The Author(s) 2013

Authors and Affiliations

  • Bo Qin
    • 1
    • 2
    • 3
  • RongJuan Pei
    • 1
  • TingTing He
    • 2
  • ZhaoHui Huang
    • 2
  • GuoShao Pan
    • 2
  • ChunYu Tu
    • 2
  • MengJi Lu
    • 1
    • 3
  • XinWen Chen
    • 1
  1. 1.State Key Laboratory of Virology, Wuhan Institute of VirologyChinese Academy of SciencesWuhanChina
  2. 2.Shaoxing Centre for Disease Control and PreventionShaoxingChina
  3. 3.Institute of VirologyUniversity Hospital of EssenEssenGermany

Personalised recommendations